SCHEMBL14025720

SCHEMBL14025720

O=S(=O)(NCc1ccccc1)c1cccc(CN2CCCCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
LMNA P02545 4/20 0.61
PKM P14618 1/20 0.61
RAB9A P51151 1/20 0.61
KDM4E B2RXH2 1/20 0.56
POLB P06746 1/20 0.56
KEAP1 Q14145 1/20 0.56
HTT P42858 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HPGD P15428 2/20 0.56
HDAC2 Q92769 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
HTR7 P34969 1/20 0.51
HSD11B1 P28845 2/20 0.51
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
HIF1A Q16665 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025724 0.99 ALDH1A1 (0.63) ALDH1A1LMNAPKMRAB9AKDM4E
SCHEMBL14025727 0.87 ALDH1A1 (0.59) ALDH1A1LMNAPKMRAB9AKDM4E
SCHEMBL14025573 0.87 CHRM3 (0.62) ALDH1A1LMNAPKMRAB9AKDM4E
SCHEMBL14025545 0.86 ALDH1A1 (0.67) ALDH1A1LMNAKDM4EPOLBKEAP1
SCHEMBL14025599 0.86 LMNA (0.61) ALDH1A1LMNAPKMRAB9APOLB
SCHEMBL14025542 0.85 ALDH1A1 (0.68) ALDH1A1LMNAKDM4EPOLBKEAP1
SCHEMBL13574563 0.77 PRMT6 (0.57) ALDH1A1KDM4ESMN1; SMN2CYP2D6CYP2C9
SCHEMBL13293744 0.77 DRD2 (0.60) ALDH1A1KDM4ESMN1; SMN2CYP2D6CYP2C9
SCHEMBL14025561 0.77 KEAP1 (0.71) ALDH1A1LMNAPKMRAB9AKEAP1
SCHEMBL4615322 0.76 KEAP1 (0.69) ALDH1A1LMNAPKMRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885LMNA 2811/4885PKM 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.